Nkarta (NKTX) IPO Opens 204% Higher

Today's IPO for Nkarta, Inc. (NASDAQ: NKTX) opened for trading at $54.75 after pricing 14,000,000 shares of common stock at a public offering price of $18.00 per share.

In addition, Nkarta has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price.

Cowen, Evercore ISI, Stifel and Mizuho Securities are acting as joint book-running managers for the offering.

Nkarta, Inc. focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta’s mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients

You May Also Be Interested In

• Standard Nuclear launches IPO roadshow targeting up to $21 per share
• JPMorgan on SpaceX-Tesla merger: strategically sound but overly complex
• Alignment Healthcare: Allegations Are Wholly Without Merit - Bloomberg